Cargando…

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Zeidner, Joshua F., Lin, Tara L., Vigil, Carlos E., Fine, Gil, Yair Levy, M., Nazha, Aziz, Esteve, Jordi, Lee, Daniel J., Yee, Karen, Dalovisio, Andrew, Wang, Eunice S., Bergua Burgues, Juan M., Schriber, Jeffrey, Litzow, Mark R., Frankfurt, Olga, Castillo, Teresa Bernal Del, Bhatt, Vijaya Raj, Bhatnagar, Bhavana, Mehta, Priyanka, Dillon, Richard, Vicente, Maria Vidriales, Anthony, Stephen, Bearss, David, Montesinos, Pau, Douglas Smith, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557202/ https://www.ncbi.nlm.nih.gov/pubmed/34718324 http://dx.doi.org/10.1038/s41408-021-00568-3

Ejemplares similares

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
por: Patzke, Ciera L., et al.
Publicado: (2020)

Modulation of Primary Cilia by Alvocidib Inhibition of CILK1
por: Wang, Elena X., et al.
Publicado: (2022)

Mitochondrial Priming of Chronic Lymphocytic Leukemia Patients Associates Bcl-x(L) Dependence with Alvocidib Response
por: Pierceall, William E., et al.
Publicado: (2014)

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023)

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
por: Wang, Amy Y., et al.
Publicado: (2018)

The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells
por: Zocchi, Loredana, et al.
Publicado: (2018)

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study
por: Braess, Jan, et al.
Publicado: (2018)

Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
por: Tisi, Maria Chiara, et al.
Publicado: (2023)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
por: Gill, Harinder, et al.
Publicado: (2020)

Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma
por: Zhang, Xu Hannah, et al.
Publicado: (2021)

Alvocidib inhibits IRF4 expression via super‐enhancer suppression and adult T‐cell leukemia/lymphoma cell growth
por: Sakamoto, Hikaru, et al.
Publicado: (2022)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
por: Miguel Bergua Burgues, Juan, et al.
Publicado: (2023)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
por: Zhang, Jingyi, et al.
Publicado: (2022)

CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1
por: Yakymiv, Yuliya, et al.
Publicado: (2021)

Successful Treatment of Multifocal Histiocytic Sarcoma Occurring after Renal Transplantation with Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) Followed by Allogeneic Hematopoietic Stem Cell Transplantation
por: Tomlin, Julia, et al.
Publicado: (2015)

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study
por: Halpern, Anna B., et al.
Publicado: (2017)

A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
por: Resta, Lee P., et al.
Publicado: (2010)

Mitoxantrone and Mitoxantrone-Loaded Iron Oxide Nanoparticles Induce Cell Death in Human Pancreatic Ductal Adenocarcinoma Cell Spheroids
por: Dinter, Jonas, et al.
Publicado: (2023)

Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes
por: Attwa, Mohamed W., et al.
Publicado: (2023)

Mitoxantrone-Surfactant Interactions: A Physicochemical Overview
por: Enache, Mirela, et al.
Publicado: (2016)

Late Cardiotoxicity in MS Patients Treated with Mitoxantrone
por: Najafian, Jamshid, et al.
Publicado: (2019)

Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG
por: Linder, Katherine, et al.
Publicado: (2016)

Cytarabine-Induced Encephalitis
por: Lenfant, Christine, et al.
Publicado: (2021)

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
por: Freiburghaus, Catja, et al.
Publicado: (2018)

Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone
por: Altmann, Sharon E., et al.
Publicado: (2012)

The impact of age on a mitoxantrone-based tumor vaccine
por: Stonewall, Keven, et al.
Publicado: (2013)

Inhibitory Effect of Mitoxantrone on Collagen Synthesis in Dermal Fibroblasts
por: Kim, Kyung-Il, et al.
Publicado: (2022)

Rational design of a new cytarabine-based prodrug for highly efficient oral delivery of cytarabine
por: Zhang, Jing, et al.
Publicado: (2018)

Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
por: Vukovic, V., et al.
Publicado: (1997)

Anthracycline antibiotics derivate mitoxantrone—Destructive sorption and photocatalytic degradation
por: Štenglová-Netíková, Irena R., et al.
Publicado: (2018)

Enhancing the Therapeutic Efficacy of Daunorubicin and Mitoxantrone with Bavachinin, Candidone, and Tephrosin
por: Darzi, Sina, et al.
Publicado: (2019)

Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine
por: Sterner, Rosalie M., et al.
Publicado: (2017)

A novel cytarabine crystalline lipid prodrug: Hexadecyloxypropyl cytarabine 3′,5′-cyclic monophosphate for proliferative vitreoretinopathy
por: Kim, Jae Suk, et al.
Publicado: (2012)

Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells
por: Skladanowski, A, et al.
Publicado: (2000)

Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.
por: Rentsch, K. M., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_fn7jfhm4vtmbbn5en20h8vak0k